Gale R, Gill C, Pikoula M, et al. - In the present study, the researchers sought to evaluate the efficacy, burden and safety of two categories of treatment for central retinal vein occlusion (CRVO): intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) and dexamethasone (Ozurdex). Four thousand six hundred twenty-six treatment-naive patients with a single mode of treatment for macular oedema secondary to CRVO were found in a retrospective analysis of Medisoft electronic medical record data from 27 National Health Service sites in the UK identified. Data reported that mean VA was 47.9 and 45.3 EDTRS letters in the anti-VEGF and Ozurdex groups, respectively. With anti-VEGF treatment, VA improvements were greater and more sustained. In both groups, lower starting acuity resulted in larger gains, while greater starting acuity resulted in higher VA at 36 months. Although treatment burden was higher with anti-VEGF, Ozurdex was related to higher rates of endophthalmitis.